HUP0303480A2 - 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények - Google Patents

4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303480A2
HUP0303480A2 HU0303480A HUP0303480A HUP0303480A2 HU P0303480 A2 HUP0303480 A2 HU P0303480A2 HU 0303480 A HU0303480 A HU 0303480A HU P0303480 A HUP0303480 A HU P0303480A HU P0303480 A2 HUP0303480 A2 HU P0303480A2
Authority
HU
Hungary
Prior art keywords
methoxypyrid
pyrazolo
butylamino
methyl
crf
Prior art date
Application number
HU0303480A
Other languages
English (en)
Inventor
Paul J. Gilligan
Original Assignee
Bristol-Myers Squibb Pharma Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Co. filed Critical Bristol-Myers Squibb Pharma Co.
Publication of HUP0303480A2 publication Critical patent/HUP0303480A2/hu
Publication of HUP0303480A3 publication Critical patent/HUP0303480A3/hu
Publication of HU229317B1 publication Critical patent/HU229317B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A találmány tárgyát képezi a kortikotropin releasing faktor (CRF)receptorokat antagonizáló, és ezáltal például különböző idegrendszeribetegségek, mint például szorongás, poszt-traumatikus stresszbetegségés depresszió kezelésére alkalmas (I) képletű 4-(2-butilamino)-2,7dimetil-8-(2-metil-6-metoxipirid-3-il)[1,5-a]pirazolo-1,3,5-triazin, ennek izomerjei, sztereoizomer formái, a sztereoizomerekkeverékei, gyógyászatilag elfogadható prodrugjai vagy gyógyászatilagelfogadható sói. A találmány további tárgyát képezi az (I) képletűvegyületet és egy gyógyászatilag elfogadható hordozóanyagot tartalmazógyógyszerkészítmény, a vegyület alkalmazása - különösen CRF-receptorantagonizáló, így például szorongás vagy depresszió kezelésérehasználható - gyógyszer előállitására. Ó
HU0303480A 2001-03-13 2002-03-06 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine derivatives, and enantiomers of the same az cortikotropine releasing factor (cfr) ligands HU229317B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27540301P 2001-03-13 2001-03-13
PCT/US2002/006837 WO2002072202A1 (en) 2001-03-13 2002-03-06 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Publications (3)

Publication Number Publication Date
HUP0303480A2 true HUP0303480A2 (hu) 2004-01-28
HUP0303480A3 HUP0303480A3 (en) 2005-12-28
HU229317B1 HU229317B1 (en) 2013-10-28

Family

ID=23052141

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303480A HU229317B1 (en) 2001-03-13 2002-03-06 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine derivatives, and enantiomers of the same az cortikotropine releasing factor (cfr) ligands

Country Status (36)

Country Link
US (4) US20030125330A1 (hu)
EP (1) EP1368094B1 (hu)
JP (1) JP4549630B2 (hu)
KR (1) KR100875595B1 (hu)
CN (1) CN100427093C (hu)
AR (1) AR032986A1 (hu)
AT (1) ATE355102T1 (hu)
AU (1) AU2002245605B2 (hu)
BG (1) BG66331B1 (hu)
BR (1) BR0208357A (hu)
CA (1) CA2440553C (hu)
CY (1) CY1106607T1 (hu)
CZ (1) CZ20032481A3 (hu)
DE (1) DE60218434T2 (hu)
DK (1) DK1368094T3 (hu)
EE (1) EE05433B1 (hu)
ES (1) ES2282401T3 (hu)
GE (1) GEP20053608B (hu)
HK (1) HK1057182A1 (hu)
HR (1) HRP20030822B1 (hu)
HU (1) HU229317B1 (hu)
IL (2) IL157615A0 (hu)
IS (1) IS2839B (hu)
MX (1) MXPA03008185A (hu)
MY (1) MY146935A (hu)
NO (1) NO328580B1 (hu)
NZ (1) NZ528207A (hu)
PL (1) PL208278B1 (hu)
PT (1) PT1368094E (hu)
RS (1) RS50863B (hu)
RU (1) RU2292347C2 (hu)
SK (1) SK287603B6 (hu)
TW (1) TWI257388B (hu)
UA (1) UA74634C2 (hu)
WO (1) WO2002072202A1 (hu)
ZA (1) ZA200306995B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094782B1 (en) * 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
WO2002072202A1 (en) * 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AR041470A1 (es) 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7041671B2 (en) * 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
JP2006523675A (ja) * 2003-04-15 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロロ［１，２−ｂ］ピリダジン化合物及びそれらの使用
US7208596B2 (en) * 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en) * 2003-11-25 2006-12-26 Bristol-Myers Squibb Pharma Co. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
MX2009003125A (es) 2006-09-20 2009-05-28 Lilly Co Eli Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
KR102079844B1 (ko) 2016-09-20 2020-02-20 가톨릭대학교 산학협력단 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
CA3188730A1 (en) 2020-08-12 2022-02-17 Christopher Barnes Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
RU2153494C2 (ru) 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
JP2000507552A (ja) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU3064397A (en) 1996-05-24 1997-12-09 Dow Chemical Company, The Process for preparing aliphatic ester compounds and alkanols
PL195762B1 (pl) * 1996-07-24 2007-10-31 Bristol Myers Squibb Pharma Co Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
CZ68199A3 (cs) * 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
UA62972C2 (en) 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
WO1999001439A1 (en) 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
NZ505079A (en) * 1998-01-28 2003-08-29 Du Pont Pharm Co Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP2002510695A (ja) 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
WO2002072202A1 (en) * 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Also Published As

Publication number Publication date
NO20034023D0 (no) 2003-09-11
JP4549630B2 (ja) 2010-09-22
CY1106607T1 (el) 2012-01-25
RS50863B (sr) 2010-08-31
HUP0303480A3 (en) 2005-12-28
MXPA03008185A (es) 2004-01-29
GEP20053608B (en) 2005-09-12
SK287603B6 (sk) 2011-03-04
US20070054913A1 (en) 2007-03-08
UA74634C2 (uk) 2006-01-16
YU71503A (sh) 2006-05-25
BG108189A (bg) 2004-09-30
DK1368094T3 (da) 2007-07-02
KR100875595B1 (ko) 2008-12-23
EP1368094A1 (en) 2003-12-10
EE200300435A (et) 2003-12-15
ES2282401T3 (es) 2007-10-16
NO20034023L (no) 2003-09-11
PL368644A1 (en) 2005-04-04
US20030125330A1 (en) 2003-07-03
DE60218434D1 (en) 2007-04-12
JP2004530662A (ja) 2004-10-07
US7157578B2 (en) 2007-01-02
AU2002245605B2 (en) 2006-02-02
HRP20030822A2 (en) 2004-04-30
CN1509196A (zh) 2004-06-30
PL208278B1 (pl) 2011-04-29
HRP20030822B1 (en) 2008-01-31
AR032986A1 (es) 2003-12-03
BG66331B1 (bg) 2013-06-28
PT1368094E (pt) 2007-05-31
DE60218434T2 (de) 2007-11-08
EP1368094A4 (en) 2004-03-31
US20040014760A1 (en) 2004-01-22
KR20030080086A (ko) 2003-10-10
EP1368094B1 (en) 2007-02-28
CA2440553A1 (en) 2002-09-19
TWI257388B (en) 2006-07-01
RU2003130093A (ru) 2005-03-20
ATE355102T1 (de) 2006-03-15
SK11572003A3 (sk) 2004-02-03
CN100427093C (zh) 2008-10-22
HU229317B1 (en) 2013-10-28
NZ528207A (en) 2006-02-24
US20080139567A1 (en) 2008-06-12
EE05433B1 (et) 2011-06-15
US7662817B2 (en) 2010-02-16
IS6947A (is) 2003-09-10
NO328580B1 (no) 2010-03-22
BR0208357A (pt) 2004-06-29
MY146935A (en) 2012-10-15
IS2839B (is) 2013-06-15
ZA200306995B (en) 2004-09-08
CZ20032481A3 (cs) 2007-12-27
HK1057182A1 (en) 2004-03-19
CA2440553C (en) 2010-06-08
WO2002072202A1 (en) 2002-09-19
US7358252B2 (en) 2008-04-15
IL157615A (en) 2009-09-01
RU2292347C2 (ru) 2007-01-27
IL157615A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
HUP0303480A2 (hu) 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények
HUP9901820A2 (hu) 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301195A2 (hu) Alfa-4 integrin antagonista hatású aza-hidas biciklusos aminosav-származékok és ilyen vegyületeket tartalmazó gyógyszerkészítmények
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
CA2401229A1 (en) Aryl fused azapolycyclic compounds
CA2523261A1 (en) Fused pyrimidine derivatives with crf activity
DE69828445D1 (de) Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
HUP0202795A2 (hu) Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
FI962155A0 (fi) Uudet 9-hydroksipyrido (1,2-a) pyrimidin-4-onieetterijohdannaiset
TW200716100A (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
HUP0105081A2 (hu) Triazolo[4,5-d]pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AU2134402A (en) Antiviral agents
HUP0204246A2 (hu) Új tiazolo[4,5-d]pirimidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
HUP0400991A2 (hu) Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 I antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
HUP0301458A2 (hu) Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
DE60214401D1 (de) Hetero-bicyclische crf antagonisten
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees